MindWalk Holdings Corp. (NASDAQ:HYFT) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• MindWalk Holdings received a consensus “Moderate Buy” rating from five analysts, with two buys, one strong buy, one hold and one sell. The average 12-month price target is $5.00, compared with shares trading at $1.50.
• BlackRock initiated a position of 154,411 shares valued at approximately $244,000, while institutional investors collectively own 6.70% of the company.
• MindWalk’s latest quarter fell short of expectations, reporting an EPS loss of $0.09 versus the projected $0.05 loss and revenue of $2.73 million versus the $3.25 million estimate. The company continues to post substantial losses, including a negative net margin of 105.11%.

MindWalk Holdings Corp. (NASDAQ:HYFT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $5.00.

Several brokerages recently weighed in on HYFT. Wall Street Zen raised shares of MindWalk from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a "buy" rating on shares of MindWalk in a research report on Monday, July 20th. Zacks Research upgraded MindWalk from a "strong sell" rating to a "hold" rating in a research note on Monday, September 21st. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of MindWalk in a research note on Wednesday, July 15th.

Institutional Investors Weigh In On MindWalk

A hedge fund recently bought a new stake in MindWalk stock. BlackRock Inc. acquired a new position in MindWalk Holdings Corp. (NASDAQ:HYFT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 154,411 shares of the company's stock, valued at approximately $244,000. BlackRock Inc. owned approximately 0.33% of MindWalk as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 6.70% of the company's stock.

MindWalk Stock Performance

Shares of HYFT stock opened at $1.50 on Thursday. The company has a market capitalization of $70.06 million, a price-to-earnings ratio of -5.77 and a beta of 0.77. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84. MindWalk has a one year low of $0.99 and a one year high of $2.99. The company's 50-day moving average is $1.36 and its 200 day moving average is $1.38.

MindWalk (NASDAQ:HYFT - Get Free Report) last issued its earnings results on Monday, September 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.25 million. MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. Sell-side analysts expect that MindWalk will post -0.28 EPS for the current fiscal year.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.